Results 11 to 20 of about 24,846 (173)

Cefotaxime/sulbactam: clinical and pharmacological characteristics [PDF]

open access: yesКлиническая микробиология и антимикробная химиотерапия, 2019
The recently approved cefotaxime/sulbactam, combination of third-generation cephalosporin (cefotaxime) and beta-lactamase inhibitor (sulbactam), can combat resistance mechanisms associated with the production of serine beta-lactamases, including some ...
Ortenberg E.A., Golub A.V.
doaj   +1 more source

Observation of substrate diffusion and ligand binding in enzyme crystals using high-repetition-rate mix-and-inject serial crystallography

open access: yesIUCrJ, 2021
Here, we illustrate what happens inside the catalytic cleft of an enzyme when substrate or ligand binds on single-millisecond timescales. The initial phase of the enzymatic cycle is observed with near-atomic resolution using the most advanced X-ray ...
Suraj Pandey   +39 more
doaj   +1 more source

In vitro synergism of combinations of colistin with selected antibiotics against colistin-resistant Acinetobacter baumannii

open access: yesGMS Hygiene and Infection Control, 2014
[english] Aim: The in vitro activity of colistin in combination with sulbactam, netilmicin, and vancomycin against colistin-resistant strains was investigated. Furthermore, the clonal relationship of the strains was analyzed.
Percin, Duygu   +2 more
doaj   +1 more source

Antibiofilm Activity of β-Lactam/β-Lactamase Inhibitor Combination against Multidrug-Resistant Salmonella Typhimurium

open access: yesPathogens, 2022
This study was designed to assess the effect of β-lactam/β-lactamase inhibitor combinations on the inhibition of biofilm formation of Salmonella Typhimurium.
Nana Nguefang Laure, Juhee Ahn
doaj   +1 more source

The Potential Role of Sulbactam and Cephalosporins Plus Daptomycin Against Daptomycin-Nonsusceptible VISA and H-VISA Isolates: An In Vitro Study

open access: yesAntibiotics, 2019
This study assesses the synergistic effect of the combination of cephalosporins and sulbactam with daptomycin against daptomycin-nonsusceptible, vancomycin-intermediate resistant Staphylococcus aureus (VISA) or heterogeneous vancomycin-intermediate S ...
Chih-Cheng Lai   +8 more
doaj   +1 more source

Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption

open access: yesFrontiers in Immunology, 2021
BackgroundABO blood type incompatibility hemolytic disease of newborn (ABO-HDN) and drug-induced immune hemolytic anemia (DIIHA) due to non-immunologic protein adsorption (NIPA) mainly cause extravascular hemolysis.
Yuanjun Wu   +7 more
doaj   +1 more source

Perioperative antibiotic prophylaxis in surgery

open access: yesPerioperative Medicine, 2021
Infectious complications in surgery occupy a significant place among the causes of death and increase in the cost of medical care for various pathologies.
Dmytro Dmytriiev   +2 more
doaj   +1 more source

Comparison of Tigecycline or Cefoperazone/Sulbactam therapy for bloodstream infection due to Carbapenem-resistant Acinetobacter baumannii

open access: yesAntimicrobial Resistance and Infection Control, 2019
Background We retrospectively analyzed the effect of tigecycline and cefoperazone/sulbactam therapies on the prognosis of patients with carbapenem-resistant Acinetobacter baumannii bloodstream infection (CRAB-BSI).
Tianshui Niu   +5 more
doaj   +1 more source

Hypothermia from a two‐component mixture comprising Amoxicillin and Sulbactam

open access: yesClinical Case Reports, 2020
Hypothermia might be an adverse effect of Amoxicillin and/or Sulbactam, and clinicians should be aware of this effect. Further clinical and laboratory investigations are also needed to confirm and clarify the underlying mechanism of this side effect.
Tung Anh Dinh Duong   +7 more
doaj   +1 more source

Targeting USP22 to promote K63-linked ubiquitination and degradation of SARS-CoV-2 nucleocapsid protein

open access: yesJournal of Virology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) generally hijacks the cellular machinery of host cells for survival. However, how SARS-CoV-2 employs the host’s deubiquitinase to facilitate virus replication remains largely unknown.
Xin Xiao   +10 more
doaj   +1 more source

Home - About - Disclaimer - Privacy